JP2020193206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020193206A5 JP2020193206A5 JP2020134010A JP2020134010A JP2020193206A5 JP 2020193206 A5 JP2020193206 A5 JP 2020193206A5 JP 2020134010 A JP2020134010 A JP 2020134010A JP 2020134010 A JP2020134010 A JP 2020134010A JP 2020193206 A5 JP2020193206 A5 JP 2020193206A5
- Authority
- JP
- Japan
- Prior art keywords
- cladribine
- administered
- phase
- total dose
- reached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 8
- 229960002436 cladribine Drugs 0.000 claims 8
- 230000006698 induction Effects 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| US60/638,669 | 2004-12-22 | ||
| EP04106909.7 | 2004-12-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018129918A Division JP2018165271A (ja) | 2004-12-22 | 2018-07-09 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020193206A JP2020193206A (ja) | 2020-12-03 |
| JP2020193206A5 true JP2020193206A5 (enExample) | 2021-08-19 |
Family
ID=36227798
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547486A Expired - Lifetime JP5795456B2 (ja) | 2004-12-22 | 2005-12-20 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2013113850A Expired - Lifetime JP5908863B2 (ja) | 2004-12-22 | 2013-05-30 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2015120875A Expired - Lifetime JP6092945B2 (ja) | 2004-12-22 | 2015-06-16 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2016078293A Expired - Lifetime JP6290962B2 (ja) | 2004-12-22 | 2016-04-08 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2017022375A Expired - Lifetime JP6430554B2 (ja) | 2004-12-22 | 2017-02-09 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2018129918A Pending JP2018165271A (ja) | 2004-12-22 | 2018-07-09 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2020134010A Pending JP2020193206A (ja) | 2004-12-22 | 2020-08-06 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547486A Expired - Lifetime JP5795456B2 (ja) | 2004-12-22 | 2005-12-20 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2013113850A Expired - Lifetime JP5908863B2 (ja) | 2004-12-22 | 2013-05-30 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2015120875A Expired - Lifetime JP6092945B2 (ja) | 2004-12-22 | 2015-06-16 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2016078293A Expired - Lifetime JP6290962B2 (ja) | 2004-12-22 | 2016-04-08 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2017022375A Expired - Lifetime JP6430554B2 (ja) | 2004-12-22 | 2017-02-09 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
| JP2018129918A Pending JP2018165271A (ja) | 2004-12-22 | 2018-07-09 | 多発性硬化症を治療するためのクラドリビン投薬計画 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7713947B2 (enExample) |
| EP (7) | EP4523753A3 (enExample) |
| JP (7) | JP5795456B2 (enExample) |
| KR (1) | KR20070091662A (enExample) |
| AR (1) | AR052830A1 (enExample) |
| AU (2) | AU2005318190B2 (enExample) |
| BR (1) | BRPI0517132B8 (enExample) |
| CA (2) | CA3087419C (enExample) |
| CY (3) | CY1112614T1 (enExample) |
| DK (3) | DK4070800T3 (enExample) |
| EA (1) | EA015799B1 (enExample) |
| ES (2) | ES3007339T3 (enExample) |
| FI (1) | FI4070800T3 (enExample) |
| FR (1) | FR18C1008I2 (enExample) |
| HR (1) | HRP20120228T1 (enExample) |
| HU (3) | HUE070333T2 (enExample) |
| IL (2) | IL183930A0 (enExample) |
| LT (3) | LT3332789T (enExample) |
| LU (1) | LUC00064I2 (enExample) |
| MX (1) | MX2007007610A (enExample) |
| NO (1) | NO20073813L (enExample) |
| PL (4) | PL4070800T3 (enExample) |
| SG (1) | SG160391A1 (enExample) |
| SI (3) | SI2805723T1 (enExample) |
| WO (1) | WO2006067141A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3007339T3 (en) | 2004-12-22 | 2025-03-19 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
| EA020805B1 (ru) | 2006-05-24 | 2015-01-30 | Мерк Сероно С.А. | Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) * | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| CN119097635A (zh) * | 2017-11-24 | 2024-12-10 | 默克专利股份公司 | 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法 |
| GB2601786A (en) * | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| JPH10512549A (ja) | 1994-12-22 | 1998-12-02 | オーソ・フアーマシユーチカル・コーポレーシヨン | 可溶性の２−クロロ−２’−デオキシアデノシン配合物 |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| EP1556400B1 (en) | 2002-09-25 | 2013-05-01 | Brigham Young University | Method for the preparation of 2-halo-2 -deoxyadenosine compounds from 2 -deoxyguanosine |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| WO2004075903A1 (en) * | 2003-02-25 | 2004-09-10 | Applied Research Systems Ars Holding N.V. | Combined use of ribavirin and interferon beta in demyelinating diseases |
| DK2272503T3 (da) * | 2003-03-28 | 2013-05-21 | Ares Trading Sa | Orale formuleringer af cladribin |
| EA009714B1 (ru) | 2003-03-28 | 2008-02-28 | Арес Трейдинг С.А. | Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки |
| ES3007339T3 (en) | 2004-12-22 | 2025-03-19 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
| EA020805B1 (ru) * | 2006-05-24 | 2015-01-30 | Мерк Сероно С.А. | Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза |
-
2005
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 CA CA3087419A patent/CA3087419C/en not_active Expired - Lifetime
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en not_active Ceased
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en active Pending
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 CA CA2588966A patent/CA2588966C/en not_active Expired - Lifetime
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en not_active Expired - Lifetime
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en not_active Expired - Lifetime
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en not_active Expired - Lifetime
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en not_active Expired - Lifetime
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en not_active Expired - Lifetime
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I1/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending